BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21337343)

  • 1. TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome.
    Hoven-Gondrie ML; Bastiaannet E; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
    J Surg Oncol; 2011 Jun; 103(7):648-55. PubMed ID: 21337343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
    Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
    J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients.
    Deroose JP; van Geel AN; Burger JW; Eggermont AM; Verhoef C
    J Surg Oncol; 2012 May; 105(6):563-9. PubMed ID: 22020863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
    Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas.
    Deroose JP; Grünhagen DJ; de Wilt JH; Eggermont AM; Verhoef C
    Eur J Cancer; 2015 Feb; 51(3):367-73. PubMed ID: 25529370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?
    Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
    Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
    Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
    Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
    Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
    J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
    Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Limb perfusion in soft tissue sarcomas: twenty years of experience].
    Hoven-Gondrie ML; Bastiaannet E; van Ginkel RJ; Pras EB; Suurmeijer A; Hoekstra HJ
    Ned Tijdschr Geneeskd; 2013; 157(30):A6148. PubMed ID: 23890169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma.
    Jakob J; Hohenberger P
    Cancer; 2016 Sep; 122(17):2624-32. PubMed ID: 27197621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation.
    van Ginkel RJ; Thijssens KM; Pras E; van der Graaf WT; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2007 Apr; 14(4):1499-506. PubMed ID: 17253101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study.
    Huis In 't Veld EA; Grünhagen DJ; Verhoef C; Smith HG; van Akkooi ACJ; Jones R; van Coevorden F; Hayes AJ; van Houdt WJ
    Eur J Cancer; 2017 Nov; 85():114-121. PubMed ID: 28918185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma.
    Smith HG; Cartwright J; Wilkinson MJ; Strauss DC; Thomas JM; Hayes AJ
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S356-61. PubMed ID: 26350373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy.
    Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.
    Lans TE; Grünhagen DJ; de Wilt JH; van Geel AN; Eggermont AM
    Ann Surg Oncol; 2005 May; 12(5):406-11. PubMed ID: 15915375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies.
    Smith HG; Wilkinson MJ; Smith MJF; Strauss DC; Hayes AJ
    Eur J Cancer; 2018 Sep; 100():46-54. PubMed ID: 29940423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower limb function and quality of life after ILP for soft-tissue sarcoma.
    Podleska LE; Kaya N; Farzaliyev F; Pöttgen C; Bauer S; Taeger G
    World J Surg Oncol; 2017 Apr; 15(1):84. PubMed ID: 28403880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; van Geel AN; Eggermont AM
    Cancer; 2006 Jan; 106(1):156-62. PubMed ID: 16323177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.